Login to Your Account

SABC roundup

Friday, December 13, 2013
Synta Pharmaceuticals Corp., of Lexington, Mass., presented results from the single-arm, multicenter Phase II proof-of-concept ENCHANT-1 trial evaluating the efficacy and safety of lead candidate ganetespib as monotherapy to treat HER2+ (Cohort A) or triple-negative, or TNBC (Cohort B), patients previously untreated for locally advanced or metastatic disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription